Deze website met internetadres http://www.pfizerpro.nl en alle hierop vermelde informatie is uitsluitend gericht op inwoners van Nederland.

Zoek

Menu

Close

Inloggen of registrerenUitloggenOnze geneesmiddelenZiektebeeldenOntdek meerOntdek meerEducatieMaterialenVideo'sPodcastOver PfizerOver PfizerNieuwsBlogsMedewerkers in beeldContactContactNeem gerust contact met ons opStel een vraagPfizer medische informatie

Onderaan de pagina kunt u bijwerkingen melden.

Home

Menu

Close

EfficacyEfficacy DataTrial DesignClinical RemissionEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesEventsMaterialsVideos
The convenience of one pill, once a day1

With VELSIPITY, you can offer patients 16 years of age and older1:

One pill, once a day

2 mg orally once daily, taken with food for the first 3 days, then with or without food thereafter*

The same dose right from the start—no titration required

The initiation dose is the maintenance dose

Recommended monitoring for certain safety signals
No known interactions with monoamine oxidase (MAO) inhibitors or tyramine.1,2No required scheduled monitoring outside of standard clinical assessments. Safety signals should be monitored during treatment and managed appropriately, as recommended in the Summary of Product Characteristics for VELSIPITY (etrasimod).Getting started with VELSIPITY

Test to determine if VELSIPITY is appropriate for patients before starting treatment1

  • Exclude patients who1:
    • Had certain cardiovascular conditions,* including stroke, in the last 6 months
    • Are or who plan to become pregnant
  • Please see Summary of Product Characteristics for all contraindications and special warnings and precautions for use
  • Obtain a recent (ie, within the last 6 months or after discontinuation of prior UC therapy) complete blood count with differential and liver function tests—including lymphocyte count, transaminase levels, and bilirubin levels
  • Electrocardiogram (ECG or EKG)
  • Pregnancy test
A reminder of other standard assessments
  • Vaccinations (recommended to update immunizations in agreement with current guidelines—no herpes zoster vaccine is required)
  • Obtain an eye exam of the fundus, including the macula, near or following the start of treatment to screen for any preexisting eye conditions. Patients with a history of diabetes mellitus, uveitis, or an underlying/coexisting retinal disease are recommended to undergo an eye exam regularly during treatment1

AFTER THE LAST DOSE1:

  • Women of childbearing potential should use effective contraception for at least 14 days
  • Vigilance for infection should be continued for up to 2 weeks
  • Use of live attenuated vaccine should be avoided for up to 2 weeks due to risk of infection
Patients in the last 6 months who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalization, or New York Heart Association (NYHA) class III or class IV heart failure. Patients with history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker.1Due to the risk of transient decreases in heart rate with the initiation of VELSIPITY, 4-hour monitoring for signs and symptoms of symptomatic bradycardia after the first dose is recommended in patients with resting heart rate <50 bpm, second-degree AV block (Mobitz type I), or a history of myocardial infarction or heart failure.1
Resources for your patients

See the different resources available to help your patients start and stay on VELSIPITY.

See Resources Loading
References:VELSIPITY (etrasimod) Summary of Product Characteristics. Brussels, Belgium: Pfizer Europe; February 2024. ZEPOSIA [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol Myers Squibb company; August 2023. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.
PP-V1A-NLD-0012

Wilt u een bijwerking melden? Ga dan naar de 'Bijwerkingen melden' pagina en klik vervolgens op u van toepassing zijnde button.

PfizerPro AccountPfizerPro AccountU vindt informatie over geneesmiddelen, werkingsmechanismen, werkzame stoffen, doseringen en bijwerkingen die kunnen optreden. Zodat u nog beter in staat bent om uw patiënten te helpen.InloggenRegistrerenAccountUitloggen

De informatie die op deze website wordt aangeboden is uitsluitend bedoeld voor zorgverleners in Nederland. Bent u geen zorgverlener, maar patiënt of consument, ga dan naar www.pfizer.nl.

 

2025 Pfizer© Alle rechten voorbehouden.
 

PP-V1A-NLD-0012
U verlaat de website van Pfizer
Door op oké te klikken, verlaat u de website van Pfizer. De links naar websites buiten Pfizer worden u als service aangeboden. Pfizer heeft geen invloed op de inhoud van deze sites en is er niet voor verantwoordelijk.